Want to join the conversation?
$ABBV 2Q15 Call: The acquisition of Pharmacyclics will also drive strong financial benefits, further diversifying our revenue base significantly enhancing our revenue growth. We expect accretion related to the acquisition in excess of $0.60 per share in 2019 ramping to more than a dollar per share in 2021.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)